LP
ANTH

LMR Partners’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

LMR Partners’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-28,743
Closed -$47K – 659
2017
Q2 		$47K Buy
+28,743
New +$64.4K ﹤0.01% 588

Other funds holding ANTH

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

LMR Partners's ANTH Position: Q3 2017 in Review

LMR Partners sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q3 2017, closing a stake of 28,743 shares — an estimated $47K sold.

LMR Partners first reported a position in ANTH in Q2 2017 and held it in 1 quarter. The position peaked at $47K in Q2 2017. 35 funds tracked by Wall St. Rank hold ANTH as of Q3 2017.

  • LMR Partners reported no remaining Anthera Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • LMR Partners sold 28,743 Anthera Pharmaceuticals, Inc. shares in Q3 2017, an estimated $47K.
  • LMR Partners first reported a position in Anthera Pharmaceuticals, Inc. in Q2 2017 and held it in 1 quarter.
  • LMR Partners's Anthera Pharmaceuticals, Inc. position peaked at $47K in Q2 2017.
  • 35 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q3 2017.

Based on LMR Partners's 13F filing for Q3 2017, filed 9 Nov 2017.